Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer

British Medical Journal

Volumn 327, Issue 7413, 2003, Pages 469-472

  Ross, J R ^a   Saunders, Y ^a   Edmonds, P M ^b   Patel, S ^c   Broadley, K E ^c   Johnston, S R D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE METASTASIS; CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; META ANALYSIS; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; SPINAL CORD COMPRESSION;

BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; RANDOMIZED CONTROLLED TRIALS; SPINAL CORD COMPRESSION; SPINAL FRACTURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041352250     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Healey JH, Brown HK. Complications of bone metastases. Surgical management. Cancer 2000;88:2940-51.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(suppl):1588-94.
3. Fleisch H. Bisphosphonates: mechanism of action. Endocr Rev 1998;9:80-100.
4. Francis M, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in-vitro and pathalogical calcification in-vivo. Science 1969;165:1264-6.
5. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin Oncol 2001;28(2 suppl 6):35-44.
6. Russell RG, Rogers M, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Min Res 1999;14(suppl 2):53-65.
7. Luckman SP, Hughes DE, Coxon FP, Russell RG, Rogers MJ. Nitrogen-containing bisphosphonate inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Min Res 1998;13:581-9.
8. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, et al. Protein Geranylgeranylation is required for osteoclast formation, function and survival: inhibition by bisphosphonates and GGTI-298.J Bone Min Res 2000;15:1467-6.
9. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999;24(5 suppl):73-9s.
10. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2003;(2):CD002068.
11. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology bisphosphonates expert panel. J Clin Oncol 2000;18:1378-91.
12. Bishop HM, Cameron DA, Coleman R, Davies AM, Dewar JA, Evans A, et al. British Association of Surgical Oncology Guidelines. Eur J Surg Oncol 1999;25:3-23.
13. Grill V, Martin TJ. Hypercalcaemia of malignancy. Rev Endocr Metab Dis 2001;1:253-63.
14. Mundy GR. Hypercalcaemia associated with hematologic malignancies. In: Mundy GR, ed. Calcium homeostasis: hypercalcaemia and hypocalcaemia. London: Martin Dunitz, 1990:100-15.
15. Pavoakis N, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Re'v 2003;(2):CD003474.
16. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2003;(2):CD003188.
17. Dearnaley DP, Sydes MR. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC Pr05 trial. J Clin Oncol (ASCO) 2001;A693.
18. Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2003 (in press).
19. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20:3219-24.
20. Yakatan GJ, Poyner WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982;31:402-10.
21. Fitton A, McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991;41:289-318.